Gandhinagar News

Hypertrophic Cardiomyopathy (HCM) Market Size, Share, Growth, Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast

 Breaking News
  • No posts were found

Hypertrophic Cardiomyopathy (HCM) Market Size, Share, Growth, Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast

February 08
16:40 2021
Hypertrophic Cardiomyopathy (HCM) Market Size, Share, Growth, Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Hypertrophic Cardiomyopathy (HCM) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Hypertrophic Cardiomyopathy (HCM), historical and forecasted epidemiology as well as the Hypertrophic Cardiomyopathy (HCM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease and an important cause of sudden death and heart failure symptoms. The current prevalence for Hypertrophic Cardiomyopathy (HCM) is based on echocardiographic population studies in which a substantial proportion of affected subjects have not come to clinical recognition. In addition, most patients with HCM never develop (or recognize) cardiovascular symptoms, experience an adverse disease-related event, or are identified with another clinical marker (e.g., abnormal electrocardiogram and family history) which could lead to clinical Recognition.

hypertrophic cardiomyopathy (HCM) can affect people of any age. It affects men and women equally but sometimes the prevalence of HCM is evaluated more in men as compared to women. It is a common cause of sudden cardiac arrest in young people, including young athletes.

Get FREE sample copy at: 
https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market

The Hypertrophic Cardiomyopathy market report also covers emerging drugs, current treatment practices, Hypertrophic Cardiomyopathy (HCM) market share of the individual therapies, current and forecasted Hypertrophic Cardiomyopathy (HCM) Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Hypertrophic Cardiomyopathy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

 

Hypertrophic Cardiomyopathy (HCM) Market

 

Hypertrophic Cardiomyopathy (HCM) Market Key Facts
As per the US National Library of medicine 2019, the familial form of HOCM is an autosomal dominant genetically transmitted disorder. It is the most common genetically transmitted cardiomyopathy, which can also occur in individuals without family history secondary to de novo mutations. Familial hypertrophic cardiomyopathy affects about 1 in 500 people worldwide. It is the most common genetic heart disease in the United States.

As per Husser et al. (2018), in Germany Hypertrophic Cardiomyopathy (HCM) prevalence increased gradually with age from 7.4/100,000 persons in 0–9 years old to 298.7/100,000 persons in patients >80 years. In all age categories, men had a numerically higher prevalence than women.

Various studies show a higher prevalence of Hypertrophic Cardiomyopathy (HCM) in males as compared to females

As per the article by Marian et al. (2017), the prevalence of Hypertrophic Cardiomyopathy has been estimated at 0.16% to 0.29% in the general adult population.

Key Benefits of Hypertrophic Cardiomyopathy (HCM) Market Report

  • Hypertrophic Cardiomyopathy (HCM) market report provides an in-depth analysis of Hypertrophic Cardiomyopathy (HCM) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.

  • The Hypertrophic Cardiomyopathy market report will help in developing business strategies by understanding the Hypertrophic Cardiomyopathy (HCM) Market trends & developments, key players, and future market competition that will shape and drive the Hypertrophic Cardiomyopathy (HCM) market in the upcoming years.

  • The Hypertrophic Cardiomyopathy (HCM) market report covers Hypertrophic Cardiomyopathy’s current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Hypertrophic Cardiomyopathy (HCM) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Hypertrophic Cardiomyopathy (HCM) Market
The Hypertrophic Cardiomyopathy (HCM) market size is expected to increase during the forecast period owing to the increasing prevalent population of Hypertrophic Cardiomyopathy in the 7MM.

The Hypertrophic Cardiomyopathy (HCM) market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Hypertrophic Cardiomyopathy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Hypertrophic Cardiomyopathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Hypertrophic Cardiomyopathy (HCM) Epidemiology
The Hypertrophic Cardiomyopathy (HCM) epidemiology section covers insights about the historical and current Hypertrophic Cardiomyopathy (HCM) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Hypertrophic Cardiomyopathy (HCM) Drugs Uptake and Key Market Players
The Hypertrophic Cardiomyopathy Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypertrophic Cardiomyopathy market or expected to get launched in the market during the study period. The analysis covers Hypertrophic Cardiomyopathy market uptake by drugs; patient uptake by therapies; and sales of each drug.  

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Companies across the globe are working toward the development of new treatment therapies for Hypertrophic Cardiomyopathy, but few companies have made it to the clinical stage of development. The dynamics of the Hypertrophic Cardiomyopathy market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, and incremental healthcare spending across the world.

Hypertrophic Cardiomyopathy (HCM) Companies:
MyoKardia
Cytokinetics
Novartis
Celltrion
Palatin Technologies
And many others.

Hypertrophic Cardiomyopathy (HCM) Therapies:
Mavacamten
CK-274
LCZ-696
MYK-224
PL-5028
And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Hypertrophic Cardiomyopathy (HCM) Competitive Intelligence Analysis

4. Hypertrophic Cardiomyopathy (HCM) Market Overview at a Glance

5. Hypertrophic Cardiomyopathy (HCM) Disease Background and Overview

6. Hypertrophic Cardiomyopathy (HCM) Patient Journey

7. Hypertrophic Cardiomyopathy (HCM) Epidemiology and Patient Population

8. Hypertrophic Cardiomyopathy (HCM) Treatment Algorithm, Current Treatment, and Medical Practices

9. Hypertrophic Cardiomyopathy (HCM) Unmet Needs

10. Key Endpoints of Hypertrophic Cardiomyopathy (HCM) Treatment

11. Hypertrophic Cardiomyopathy (HCM) Marketed Products

12. Hypertrophic Cardiomyopathy (HCM) Emerging Therapies

13. Hypertrophic Cardiomyopathy (HCM) Seven Major Market Analysis

14. Attribute Analysis

15. Hypertrophic Cardiomyopathy (HCM) Market Outlook (7 major markets)

16. Hypertrophic Cardiomyopathy (HCM) Access and Reimbursement Overview

17. KOL Views on the Hypertrophic Cardiomyopathy (HCM) Market.

18. Hypertrophic Cardiomyopathy (HCM) Market Drivers

19. Hypertrophic Cardiomyopathy (HCM) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Delveinsight’s Latest BioPharma Blog –
Cystic Fibrosis Treatment Market Analysis 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/gandhinagarnews.org/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share